公开(公告)号：EP4461368A1

公开(公告)日：2024-11-13

申请号：EP23305754.6

申请日：2023-05-12

申请人： Institut Regional du Cancer de Montpellier ,  Institut National de la Santé et de la Recherche Médicale ,  UNIVERSITE DE MONTPELLIER ,  Greenpharma

发明人： LINARES, Laetitia ,  CISSE, Madi ,  FIRMIN, Nelly ,  CARRERE, Sebastien ,  GUILLAUMET, Gérald ,  FRANCOIS, Benjamin ,  DO, Quoc Tuan ,  BERNARD, Philippe

IPC分类号： A61P35/00 ,  C07D471/14 ,  C07D519/00 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/4985 ,  A61K31/4709 ,  A61K31/4725

摘要： The present application relates to a compound of formula (I), or any of its pharmaceutically acceptable salt:

wherein R 1 represents a (C 1 -C 6 )alkyl group, a (C 3 -C 6 )cycloalkyl group, a (C 2 -C 6 )alkenyl group or a (C 1 -C 6 )alkoxy group, X and Y independently represent a -CH= group, a -CR 3 = group or a -N= group, Z1 and Z2 independently represent a -CH 2 - group, a =CH- group or a =N- group and R3 represents a hydrogen atom or a halogen atom.
It further relates to such a compound for its use as a medicament, and in particular for its use in treating and/or prevention of cancer, in particular cancer exhibiting recruitment of MDM2 to chromatin, more particularly selected from the group consisting of bone cancer, brain cancer, ovary cancer, breast cancer, lung cancer, colorectal cancer, osteosarcoma, skin cancer, blood cancer, including acute myeloid leukemia, pancreatic cancer, prostate cancer and liposarcoma and even more particularly selected from the group consisting of skin cancer, blood cancer, for example but not limited to acute myeloid leukemia, melanoma and liposarcoma.

公开(公告)号：EP4446312A1

公开(公告)日：2024-10-16

申请号：EP23737317.0

申请日：2023-01-06

申请人： CHUGAI SEIYAKU KABUSHIKI KAISHA

发明人： KIMBARA Atsushi ,  HARADA Takeo ,  KOMIYAMA Susumu ,  OKUYAMA Mizuki ,  OHTAKE Yoshihito ,  MURATA Yoshihisa ,  SAITO Rie

IPC分类号： C07D217/06 ,  A61K31/472 ,  A61K31/4725 ,  A61K31/5377 ,  A61K31/5386 ,  A61K31/541 ,  A61K31/5415 ,  A61K31/551 ,  A61P11/00 ,  A61P13/12 ,  A61P25/00 ,  A61P43/00 ,  C07D237/32 ,  C07D265/14 ,  C07D279/08 ,  C07D401/10 ,  C07D401/14 ,  C07D403/10 ,  C07D413/10 ,  C07D413/12 ,  C07D417/10

摘要： Provided is a low-molecular compound or a salt thereof, or a solvate thereof which has the ability to activate Nrf2.
The present invention provides a compound represented by the formula (1) or a salt thereof, or a solvate thereof, wherein X a1 is CR a1 or N, X a3 is CR a3 or N, R a1 , R a2 and R a3 are each independently selected from the group consisting of hydrogen, halogen and C 1 -C 6 alkoxy, X b1 , X b2 and X b3 are each independently selected from the group consisting of CH 2 , O, NH, S and C=O, Y is C 6 -C lO aryl optionally having a substituent or 5- to 10-membered heteroaryl optionally having a substituent, and Z is C 6 -C lO aryl optionally having a substituent, 5- to 10-membered heteroaryl optionally having a substituent or C 1 -C 6 alkyl optionally having a substituent.

公开(公告)号：EP3877364B1

公开(公告)日：2024-08-21

申请号：EP19881800.7

申请日：2019-11-06

IPC分类号： C07D217/02 ,  C07D217/24 ,  C07D405/06 ,  A61K31/4725 ,  A61P9/00

CPC分类号： C07D403/12 ,  C07D401/12 ,  C07D471/04 ,  A61P9/00

公开(公告)号：EP3784226B1

公开(公告)日：2024-08-14

申请号：EP19791620.8

申请日：2019-04-24

IPC分类号： C07D213/56 ,  C07D231/12 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/12 ,  C07D413/12 ,  A61K31/166 ,  A61K31/444 ,  A61K31/4725 ,  A61K31/4035 ,  A61K31/4409 ,  A61K31/4433 ,  A61K31/553 ,  A61K31/415 ,  A61K31/4155 ,  A61P35/00 ,  A61P35/02 ,  A61P35/04

CPC分类号： C07D401/12 ,  C07D213/56 ,  C07D405/12 ,  C07D413/12 ,  C07D401/14 ,  C07D403/12 ,  C07D231/12 ,  C07D401/04 ,  A61P35/00 ,  A61P35/04 ,  A61P35/02

公开(公告)号：EP4406552A1

公开(公告)日：2024-07-31

申请号：EP22872175.9

申请日：2022-09-26

申请人： CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.

发明人： SHEN, Chen ,  LV, Peng ,  TIAN, Xin ,  YANG, Ling ,  ZHANG, Xiquan

IPC分类号： A61K39/395 ,  A61P35/00 ,  A61K31/4725

CPC分类号： A61K39/395 ,  A61P35/00 ,  A61K31/4725

摘要： Provided is the use of an anti-CD40 antibody, specifically, provided is a combined drug for treating cancer. The combined drug comprises an anti-CD40 antibody or an antigen-binding portion thereof and a tyrosine kinase inhibitor, and has a good anti-tumor activity and safety.

公开(公告)号：EP4401729A1

公开(公告)日：2024-07-24

申请号：EP22870775.8

申请日：2022-09-16

申请人： Kymera Therapeutics, Inc.

发明人： AVERSA, Robert ,  YANG, Bin ,  DONG, Huijun

IPC分类号： A61K31/427 ,  A61K31/425 ,  A61K31/428 ,  A61K31/472 ,  A61K31/4725 ,  C07D277/60 ,  C07D277/62

CPC分类号： C07D417/14 ,  C07D471/04 ,  C07D513/04

公开(公告)号：EP3480193B1

公开(公告)日：2024-05-29

申请号：EP17820566.2

申请日：2017-06-30

IPC分类号： C07D401/14 ,  C07D401/04 ,  C07D233/58 ,  A61K31/4155 ,  A61K31/4725 ,  C07D417/14 ,  C07D403/04 ,  C07D403/14 ,  A61K31/428

CPC分类号： C07D401/14 ,  C07D403/04 ,  C07D417/14 ,  C07D405/14 ,  C07D413/14 ,  C07D495/04 ,  C07D471/04 ,  A61P19/04 ,  A61P17/02 ,  A61P11/00 ,  A61P19/10 ,  A61P35/00 ,  A61P1/16 ,  A61P11/06 ,  A61P13/12 ,  A61P15/10 ,  A61P17/00 ,  A61P19/02 ,  A61P25/00 ,  A61P25/28 ,  A61P27/02 ,  A61P3/10 ,  A61P35/04 ,  A61P43/00 ,  A61P7/02 ,  A61P9/00 ,  A61P9/10 ,  A61P9/12

公开(公告)号：EP4358959A1

公开(公告)日：2024-05-01

申请号：EP22829524.2

申请日：2022-06-24

申请人： Cincor Pharma, Inc.

发明人： BOND, Mary ,  MURPHY, Brian ,  PEARCE, Catherine

IPC分类号： A61K31/4725 ,  A61P5/38 ,  A61P9/12

CPC分类号： A61P9/12 ,  A61K31/4725 ,  A61P5/38

公开(公告)号：EP3939976B1

公开(公告)日：2024-05-01

申请号：EP20791861.6

申请日：2020-04-17

IPC分类号： C07D413/14 ,  A61K31/4725 ,  A61P19/00

CPC分类号： C07D413/14 ,  A61P19/00

公开(公告)号：EP4346822A1

公开(公告)日：2024-04-10

申请号：EP22740584.2

申请日：2022-06-02

申请人： GILEAD SCIENCES, INC.

发明人： BRECKENRIDGE, David G. ,  BUDAS, Grant R. ,  GUPTA, Ruchi ,  TAYLOR, James G. ,  WARR, Matthew R. ,  WRIGHT, Nathan E.

IPC分类号： A61K31/4709 ,  A61K31/4725 ,  A61K31/675 ,  A61K45/06 ,  A61K9/00 ,  A61P1/16 ,  A61P43/00